Such results indicate that deferasirox can possibly improve the antitumour effect of cisplatin in GC and that the NDRG1, p21, p53 and mTOR pathways may be associated with the synergistic effect of this drug combination [111]. Here, CDKN1A is linked to gastric cancer.